The Latest Breaking News from Alterity

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. Pfizer, Inc. shares traded in a range of $47.27 to $47.95 on day volume of 14.45 million shares, closed…

Benzinga · Aug 25, 2022

Alterity Commences Mid-Stage Neurodegenerative Disorder Study

Alterity Therapeutics (NASDAQ: ATHE) doses first subject in its Phase 2 clinical trial of lead candidate ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

Benzinga · Jul 6, 2022

British Home Stores site in Belfast to be transformed into retail and leisure development

Construction is set to be completed within 12 months

Belfast Live · Jun 28, 2022